...
首页> 外文期刊>Drug and alcohol review >Validation of the Australian Treatment Outcomes Profile for use in clients with cannabis dependence
【24h】

Validation of the Australian Treatment Outcomes Profile for use in clients with cannabis dependence

机译:验证澳大利亚治疗成果的个人资料,以便在大麻依赖性的客户中使用

获取原文
获取原文并翻译 | 示例

摘要

Abstract Introduction and Aims The Australian Treatment Outcomes Profile (ATOP) was developed as a clinical tool for monitoring the substance use, health and wellbeing of clients in alcohol and other drug treatment. This is the first psychometric validation of the ATOP in a cannabis‐dependent treatment population. Design and Methods A total of 128 individuals with cannabis dependence enrolled in an outpatient randomised controlled trial were administered the ATOP and gold‐standard health and wellbeing questionnaires once by clinicians and once by researchers at baseline. Concurrent validity was assessed by testing ATOP Psychological Health, Physical Health and Quality of Life questions against concurrently administered gold‐standard questionnaires: the Short Form 36 Health Survey (SF‐36), the 21‐item Depression, Anxiety and Stress Scale (DASS‐21) and the Sheehan Disability Scale (SDS). Interrater reliability was tested by comparing clinician‐administered ATOP items at the medical screening interview to the same ATOP items administered by researchers at baseline. Results ATOP Psychological Health showed moderate to strong correlations with SF‐36 Mental Components, SF‐36 Mental Health and DASS‐21 scores ( r = 0.40–0.52) and ATOP Physical Health with SF‐36 Physical Components and SF‐36 General Health scores ( r = 0.36–0.67). The ATOP Quality of Life scale showed moderate agreement with the SDS and six‐dimensional health state short form scales ( r = 0.38–0.40). ATOP substance use, employment, education and child care items showed good to excellent interrater reliability (Krippendorff's α = 0.62–0.81), and tobacco use, Psychological Health, Physical Health and Quality of Life showed fair to moderate interrater reliability (Krippendorff's α = 0.42–0.53). Discussion and Conclusions The ATOP appears to be valid and reliable when tested in a population with cannabis‐dependence, justifying its widespread use in clinical settings.
机译:摘要介绍和旨在澳大利亚治疗成果概况(ATOP)被制定为监测酒精和其他药物治疗的物质,健康和福祉的临床工具。这是在依赖大麻治疗人群中的第一次心理测量验证。设计和方法共有128个具有大麻依赖性的人,临床随机对照试验中的大麻依赖性由临床医生和基线研究人员进行一次临床和金标 - 标准的健康和福利问卷调查问卷。通过测试心理健康,身体健康和生命质量的测试评估并发有效性,反对同时管理的金标题问卷:短款36卫生调查(SF-36),21项抑郁,焦虑和压力量表(Dass- 21)和Sheehan残疾规模(SDS)。通过将临床医生的Atop项目进行比较来测试Interriter可靠性,以在基线的研究人员管理的同一项目的同一地点。结果表明心理健康表现出与SF-36心理成分的强烈相关性,SF-36心理健康和DASS-21分数(r = 0.40-0.52)和SF-36物理成分及SF-36普通健康成绩的身体健康(r = 0.36-0.67)。生活质量级别显示与SDS和六维健康状态短尺度(R = 0.38-0.40)进行了适度的协议。物质使用,就业,教育和儿童保育项目表现出良好的Interrater可靠性(Krippendorff'sα= 0.62-0.81),以及烟草使用,心理健康,身体健康和生活质量表现出适中的Interrater可靠性(Krippendorff的α= 0.42 -0.53)。讨论和结论在进行大麻依赖的人群中测试时,ATOP似乎有效可靠,证明其在临床环境中的广泛使用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号